Etxebarria Aitor, Benito-Vicente Asier, Palacios Lourdes, Stef Marianne, Cenarro Ana, Civeira Fernando, Ostolaza Helena, Martin Cesar
Unidad de Biofísica (CSIC, UPV/EHU) and Departamento de Bioquímica, Universidad del País Vasco, Bilbao, 48080, Spain.
Hum Mutat. 2015 Jan;36(1):129-41. doi: 10.1002/humu.22721. Epub 2014 Nov 27.
Familial hypercholesterolemia (FH) is an autosomal-dominant disorder mostly caused by mutations in the low-density lipoprotein receptor (LDLR) gene leading to increased risk for premature cardiovascular diseases. According to functional studies, LDLR mutations may be classified into five classes. The main objective of this study was to characterize seven LDLR variants previously detected in FH patients. Analysis by flow cytometry and confocal microscopy of LDLR activity demonstrate that all the studied variants are pathogenic. Among the mutations located in β-propeller, p.Trp577Gly and p.Ile624del were classified as class 2, whereas p.Arg416Trp and p.Thr454Asn as class 5. p.Phe800Glyfs*129 (located in the cytoplasmic domain), p.Cys155Tyr (located in the binding domain), and p.Asn825Lys (inside FxNPxY motif) were classified as class 2, 3, and 4, respectively. The results also show that LDLR activity of these class 4 and 5 variants is not completely abolished, showing a milder phenotype. We have also determined that statin response is more efficient lowering total cholesterol in heterozygous patients carrying p.Ile624del (class 2) compared with p.Arg416Trp and p.Thr454Asn (class 5) variants. In conclusion, these findings emphasize the importance of characterizing LDLR pathogenic variants to provide an indisputable FH diagnosis and to gain insight into the statin response depending on the LDLR class mutation.
家族性高胆固醇血症(FH)是一种常染色体显性疾病,主要由低密度脂蛋白受体(LDLR)基因突变引起,会增加早发性心血管疾病的风险。根据功能研究,LDLR突变可分为五类。本研究的主要目的是对先前在FH患者中检测到的7种LDLR变体进行特征描述。通过流式细胞术和共聚焦显微镜对LDLR活性进行分析表明,所有研究的变体均具有致病性。在位于β-螺旋桨的突变中,p.Trp577Gly和p.Ile624del被归类为2类,而p.Arg416Trp和p.Thr454Asn为5类。p.Phe800Glyfs*129(位于细胞质结构域)、p.Cys155Tyr(位于结合结构域)和p.Asn825Lys(在FxNPxY基序内)分别被归类为2类、3类和4类。结果还表明,这些4类和5类变体的LDLR活性并未完全丧失,表现出较轻的表型。我们还确定,与携带p.Arg416Trp和p.Thr454Asn(5类)变体的杂合患者相比,携带p.Ile624del(2类)的杂合患者使用他汀类药物降低总胆固醇的效果更显著。总之,这些发现强调了对LDLR致病变体进行特征描述的重要性,以便提供无可争议的FH诊断,并深入了解取决于LDLR类别突变的他汀类药物反应。